Recent studies on patterns of glucocorticoid and opioid prescribing in patients with RA, and associated harms, are reviewed.
Virginia A. Schad, PharmD, RPh, is a contributing medical author for the Haymarket Medical Network, part of the Medical Communications Group of Haymarket Media. She earned her Doctor of Pharmacy degree at the University of Pittsburgh in Pittsburgh, Pennsylvania, in 1999. For the past 20 years, Dr Schad has worked in medical communications developing numerous presentations, as well as slide libraries and kits, and editing journal articles and supplements, clinical study reports, product monographs, and program abstracts. She has also organized and implemented speaker training meetings, consultants’ meetings, advisory board meetings, roundtable meetings, and CME symposia. While Dr Schad has worked in many therapeutic areas, her areas of focus have been in endocrinology, infectious diseases, pulmonology, neurology, and cardiology.
All articles by Virginia A. Schad, PharmD, RPh
Similar Rates of Depression and Anxiety Plus Depression With Apremilast vs Other Drugs in Psoriatic Arthritis
Apremilast used for the treatment of psoriasis or psoriatic arthritis is not associated with a high risk of incident treated depression, anxiety, or anxiety plus depression.